Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, a significant increase from $2 million in the year-ago period. This growth was primarily driven by approximately $11 million in net sales of TONMYA, its recently approved treatment for fibromyalgia. The drug recorded 12,592 total prescriptions during the quarter, a 100% sequential increase, with new patient prescriptions up 36% and refills rising 207%. TONMYA currently has coverage representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels, with coverage expected to reach approximately 145 million lives once a managed Medicare agreement takes effect on Jan. 1, 2027.
The robust commercial performance underscores the market's acceptance of TONMYA, the first new treatment for fibromyalgia in over 15 years. The company's CNS commercial infrastructure, which also supports its acute migraine products Zembrace SymTouch and Tosymra, is well-positioned to leverage this momentum. As Tonix continues to expand TONMYA's market presence, the company is also advancing its clinical pipeline with a focus on high unmet medical needs.
In the second quarter, Tonix enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder (MDD). This study represents a significant step in exploring TONMYA's potential beyond fibromyalgia. Additionally, the company is preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. TNX-4800 is a monoclonal antibody that could address a critical need in Lyme disease prophylaxis.
Financially, Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents. The company stated that its resources, together with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This solid financial position provides a runway to support ongoing clinical development and commercial activities.
The implications of these results are significant for Tonix and its stakeholders. The strong sales performance of TONMYA not only validates the commercial strategy but also positions the company for sustained revenue growth. The expansion of coverage to more lives is expected to drive further prescription uptake. Moreover, the advancement of TNX-102 SL in MDD and TNX-4800 for Lyme disease highlights the company's commitment to addressing major therapeutic areas with significant unmet needs.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments. Its portfolio includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome, and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. The company's product development candidates are investigational drugs or biologics, and their efficacy and safety have not been established.
The latest news and updates relating to TNXP are available in the company's newsroom at https://nnw.fm/TNXP. For more information on Tonix, visit the press release at https://nnw.fm/6Yytj.
